Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
News|Articles|January 6, 2014
Mac Process and Schenck AccuRate To Merge and Be Renamed
Author(s)Pharmaceutical Technology Editors
Mac Process will merge with Schenck AccuRate and combine their operations under the name of Schenck Process.
Advertisement
Manufacturing for Schenck Process will continue in Whitewater, WI and Sabetha, KS and the company headquarters will be located in Kansas City, MO. Integration efforts began in 2012, resulting in streamlined processes between the two operations, which provide pneumatic conveying, filtration, weighing, and feeding systems from one supplier.
Source:
Advertisement
Related to this article
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
This article discusses risk-based lifecycle governance, system implementation considerations, and the progression of batch record control from paper-based to fully electronic systems.
Advertisement
Advertisement